Insight for strategy that delivers

Martine Leroy, Matt Bolton|5th April 2016

Healthcare is changing. Developments in treatments are taking place faster than ever, more stakeholders are involved in making decisions around treatments, and these stakeholders have different, sometimes conflicting needs. In this context, insight is key to effective marketing in meeting the challenge to deliver value to an ever-broadening range of stakeholders.

In this article, Head of Commercial Matt Bolton and Head of Insight Martine Leroy talk through how insight informs strategy at Blue Latitude Health.

What do we mean by ‘insight’?

At Blue Latitude Health, we regard insight as the deep understanding of the space where external and internal customers meet. In this context, we refer to external customers as those making decisions that impact the success of your product or service, be they patients, physicians, payers, nurses or others. Internal customers refer to those members of a healthcare company that must be engaged and motivated to deliver for external customers, from the brand team, to capability leads or compliance. Gathering insight in this sense allows us the opportunity to identify where external customers expect the business to operate and to deliver, and importantly where internal customers want and are able to operate. After all, insight is only useful if it can be acted upon. 

 

Read more about customer-centric strategy and design in issue 2 of Perspective magazine:

Our content has moved

Blue Latitude Health|18th November 2020

We’re posting all new articles on our parent website fishawack.com

read more

Fishawack Health launches Delta Magazine

Blue Latitude Health|17th November 2020

Our parent company Fishawack Health has launched a new magazine with a first issue unpacking rare disease.

read more

In the precision medicine era, the line between products and services is blurred

Amit Sheinholtz and Ilektra Safari|27th August 2020

Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?

read more